ACP
VTGN icon

Acuta Capital Partners’s VistaGen Therapeutics VTGN Stock Holding History

Acuta Capital Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-378,715
Closed -$10M – 56
2022
Q2 		$10M Sell
378,715
-12,494
-3% -$441K 5.57% 3
2022
Q1 		$14.6M Hold
391,209
– – 6.8% 3
2021
Q4 		$22.9M Buy
391,209
+275
+0.1% +$17.9K 9.62% 3
2021
Q3 		$32.1M Hold
390,934
– – 11.34% 2
2021
Q2 		$36.9M Sell
390,934
-18,925
-5% -$1.4M 14.76% 1
2021
Q1 		$26.2M Buy
409,859
+159,859
+64% +$10.7M 9.44% 1
2020
Q4 		$14.6M Buy
+250,000
New +$6.38M 3.96% 7

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acuta Capital Partners's VTGN Position: Q3 2022 in Review

Acuta Capital Partners sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 378,715 shares — an estimated $10M sold.

Acuta Capital Partners first reported a position in VTGN in Q4 2020 and held it in 7 quarters. The position peaked at $36.9M in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • Acuta Capital Partners reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 378,715 VistaGen Therapeutics shares in Q3 2022, an estimated $10M.
  • Acuta Capital Partners first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 7 quarters.
  • Acuta Capital Partners's VistaGen Therapeutics position peaked at $36.9M in Q2 2021.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on Acuta Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.